• Sab. Feb 22nd, 2025

hospitalizations

  • Home
  • A diabetes, heart failure and kidney disease medication (sotagliflozin) is the first of its kind to significantly reduce both heart attacks and strokes

A diabetes, heart failure and kidney disease medication (sotagliflozin) is the first of its kind to significantly reduce both heart attacks and strokes

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and…

CDC updates and simplifies respiratory virus recommendations

CDC released today updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19. The new guidance brings a unified approach to addressing risks from…